HighTower Advisors
DNA icon

HighTower Advisors’s Ginkgo Bioworks DNA Stock Holding History

HighTower Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-988
Closed -$9K – 3807
2024
Q2 		$9K Sell
988
-445
-31% -$13.3K ﹤0.01% 3455
2024
Q1 		$63K Sell
1,433
-450
-24% -$23.3K ﹤0.01% 3226
2023
Q4 		$130K Buy
1,883
+284
+18% +$17.4K ﹤0.01% 3134
2023
Q3 		$115K Buy
1,599
+440
+38% +$35.2K ﹤0.01% 3068
2023
Q2 		$87K Sell
1,159
-219
-16% -$13K ﹤0.01% 3098
2023
Q1 		$72K Buy
1,378
+196
+17% +$12.4K ﹤0.01% 2995
2022
Q4 		$78K Buy
1,182
+58
+5% +$5.33K ﹤0.01% 2969
2022
Q3 		$141K Sell
1,124
-284
-20% -$33.8K ﹤0.01% 2689
2022
Q2 		$133K Buy
1,408
+32
+2% +$3.9K ﹤0.01% 2721
2022
Q1 		$222K Buy
1,376
+595
+76% +$116K ﹤0.01% 2753
2021
Q4 		$260K Sell
781
-34
-4% -$16.2K ﹤0.01% 2567
2021
Q3 		$377K Buy
+815
New +$397K ﹤0.01% 2267

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HighTower Advisors's DNA Position: Q3 2024 in Review

HighTower Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 988 shares — an estimated $9K sold.

HighTower Advisors first reported a position in DNA in Q3 2021 and held it in 12 quarters. The position peaked at $377K in Q3 2021. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • HighTower Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • HighTower Advisors sold 988 Ginkgo Bioworks shares in Q3 2024, an estimated $9K.
  • HighTower Advisors first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 12 quarters.
  • HighTower Advisors's Ginkgo Bioworks position peaked at $377K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on HighTower Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.